Quality of life in patients with heart failure and improved ejection fraction: one-year changes and prognosis.

Heart failure Heart failure with improved ejection fraction Left ventricular ejection fraction Outcomes Quality of life

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
12 2022
Historique:
revised: 16 06 2022
received: 13 04 2022
accepted: 20 07 2022
pubmed: 3 8 2022
medline: 24 12 2022
entrez: 2 8 2022
Statut: ppublish

Résumé

The criteria for patients with heart failure (HF) and improved ejection fraction (HFimpEF) are a baseline left ventricular ejection fraction (LVEF) ≤40%, a ≥10-point increase from baseline LVEF, and a second LVEF measurement >40%. We aimed to (i) assess patients with HF and reduced LVEF (HFrEF) at baseline and compare quality of life (QoL) changes between those that fulfilled and those that did not fulfil the HFimpEF criteria 1 year later and (ii) assess the prognostic role of QoL in patients with HFimpEF. We reviewed data from a prospective registry of real-world outpatients with HF that were assessed for LVEF and QoL at a first visit to the HF clinic and 1 year later. QoL was evaluated with the Minnesota Living with Heart Failure Questionnaire (MLWHFQ). The primary prognostic endpoint was the composite of all-cause death or HF hospitalization. Baseline and 1-year LVEF and MLWFQ scores were available for 1040 patients with an initial LVEF ≤40% (mean age, 65.2 ± 11.7 years; 75.9% men). The main aetiology was ischaemic heart disease (52.9%), and patients were mostly in New York heart Association Classes II (71.1%) and III (21.6%). At baseline, the mean LVEF was 28.5% ± 7.3, and the mean MLWHFQ score was 30.2 ± 19.5. After 1 year, the mean LVEF increased to 38.0% ± 12.2, and the MLWHFQ scores improved to 17.4 ± 16.0. In 361 patients that fulfilled the HFimpEF criteria (34.7%), significant improvements were observed in both LVEF (from 28.7% ± 6.6 to 50.9% ± 7.6, P < 0.001) and QoL (from 32.9 ± 20.6 to 16.9 ± 16.0, P < 0.001). Patients that did not fulfil the HFimpEF criteria also showed significant improvements in LVEF (from 28.4% ± 7.6 to 31.1% ± 7.9, P < 0.001) and QoL (from 28.7 ± 18.8 to 17.6 ± 15.9, P < 0.001). However, the QoL improvement was significantly higher in the HFimpEF group (-16.0 ± 23.8 vs. -11.1 ± 20.3, P = 0.001), despite the worse mean baseline MLWHFQ score, compared with the non-HFimpEF group (P = 0.001). The 1-year QoL was similar between groups (P = 0.50). The 1-year MLWHFQ score was independently associated with outcomes; the hazard ratio for the composite endpoint was 1.02 (95% CI: 1.01-1.03, P = 0.006). In contrast, the QoL improvement (with a cut-off ≥5 points) was not independently associated with the composite outcome. Patients with HFrEF showed improved QoL after 1 year, regardless of whether they met the HFimpEF criteria. The similar 1-year QoL perception between groups suggested that factors other than LVEF influenced QoL perception. The 1-year QoL was superior to the QoL change from baseline for predicting prognosis in patients with HFimpEF.

Identifiants

pubmed: 35916351
doi: 10.1002/ehf2.14098
pmc: PMC9773756
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3804-3813

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Circ Heart Fail. 2014 May;7(3):434-9
pubmed: 24563449
J Card Fail. 2011 Feb;17(2):151-7
pubmed: 21300305
Nurs Res. 2002 Jul-Aug;51(4):209-18
pubmed: 12131233
Eur J Heart Fail. 2022 May;24(5):762-770
pubmed: 35293088
JACC Heart Fail. 2016 Mar;4(3):184-93
pubmed: 26874379
J Rehabil Med. 2001 Jul;33(4):182-6
pubmed: 11506217
J Am Coll Cardiol. 2018 Aug 7;72(6):591-601
pubmed: 30071987
J Am Coll Cardiol. 2012 May 8;59(19):1709-15
pubmed: 22554602
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
JAMA Cardiol. 2021 Aug 1;6(8):957-962
pubmed: 33950162
Eur Heart J. 2011 Oct;32(19):2395-404
pubmed: 21875859
Eur J Heart Fail. 2021 Mar;23(3):352-380
pubmed: 33605000
Rev Esp Cardiol. 2008 Mar;61(3):251-9
pubmed: 18361898
Eur J Heart Fail. 2017 Dec;19(12):1615-1623
pubmed: 28387002
Circulation. 1997 Jun 17;95(12):2660-7
pubmed: 9193435
Front Cardiovasc Med. 2021 Nov 25;8:757596
pubmed: 34901217
J Card Fail. 2004 Jun;10(3):250-7
pubmed: 15190536
JAMA Cardiol. 2017 Dec 1;2(12):1315-1321
pubmed: 29094152
Eur Heart J. 2015 Mar 14;36(11):657-68
pubmed: 25176939
Eur J Heart Fail. 2021 Apr;23(4):555-563
pubmed: 33768605
Clin Cardiol. 2008 Mar;31(3):119-24
pubmed: 18383045
Eur J Heart Fail. 2013 Jan;15(1):103-9
pubmed: 22923075
JACC Heart Fail. 2019 Apr;7(4):306-317
pubmed: 30852236
Int J Cardiol. 2013 Aug 20;167(4):1217-25
pubmed: 22507552
J Card Fail. 2000 Sep;6(3):225-32
pubmed: 10997749
JAMA Cardiol. 2016 Aug 1;1(5):510-8
pubmed: 27434402
Circ Heart Fail. 2017 Aug;10(8):
pubmed: 28784687
Heart. 2002 Mar;87(3):235-41
pubmed: 11847161
Am J Cardiol. 2013 Dec 1;112(11):1785-9
pubmed: 24012028
Mayo Clin Proc Innov Qual Outcomes. 2018 Apr 19;2(2):176-185
pubmed: 30225447
Eur J Heart Fail. 2002 Jun;4(3):337-43
pubmed: 12034160
ESC Heart Fail. 2021 Aug;8(4):3106-3118
pubmed: 34002942
Heart Fail Rev. 2020 Nov;25(6):993-1006
pubmed: 31745839
J Am Heart Assoc. 2020 Sep;9(17):e017278
pubmed: 32812460
Am J Cardiol. 1996 Oct 15;78(8):890-5
pubmed: 8888661
J Heart Lung Transplant. 2001 Sep;20(9):1016-24
pubmed: 11557198
Rev Esp Cardiol. 2004 Feb;57(2):155-60
pubmed: 14967111
Eur Heart J. 1998 Dec;19 Suppl P:P9-16
pubmed: 9886707
Eur J Heart Fail. 2010 Nov;12(11):1247-52
pubmed: 20847014
J Am Coll Cardiol. 2011 Mar 29;57(13):1468-76
pubmed: 21435516
ESC Heart Fail. 2022 Dec;9(6):3804-3813
pubmed: 35916351

Auteurs

Elisabet Zamora (E)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

Beatriz González (B)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Josep Lupón (J)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

Andrea Borrellas (A)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Mar Domingo (M)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Evelyn Santiago-Vacas (E)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Germán Cediel (G)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Pau Codina (P)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.

Carmen Rivas (C)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Ana Pulido (A)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Eva Crespo (E)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Patricia Velayos (P)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Violeta Diaz (V)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Antoni Bayes-Genis (A)

Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH